US2005010029A1PendingUtilityA1
Recombined molecules and preparation thereof
Priority: May 8, 2003Filed: May 10, 2004Published: Jan 13, 2005
Est. expiryMay 8, 2023(expired)· nominal 20-yr term from priority
Inventors:Dennis M. Brown
C12P 19/00C12P 17/04C12P 13/04C12P 7/46C12P 7/44C12P 1/00C07K 9/00C07K 1/1077C07K 1/047C07H 21/04C07H 17/08
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to novel molecules and libraries thereof as well as methods for their production. Methods of producing the novel molecules include the cleaving of starting molecules into molecular subunits and the assembly of the subunits into novel recombined molecules.
Claims
exact text as granted — not AI-modified1 . A method comprising:
a. cleaving one or more starting molecules into molecular subunits; and b. assembling two or more of said subunits to produce at least one recombined molecule which is different from said starting molecule(s), wherein at least one of said cleaving or assembling is mediated by an enzyme and wherein at least one of said recombined molecules is not a recombined nucleic acid or a recombined protein.
2 . The method of claim 1 , wherein said cleaving is of two or more different starting molecules and said recombined molecule(s) comprises intermolecular combinations of subunits from said different molecules.
3 . The method of claim 1 , wherein one or more of the molecular subunits is modified prior to said assembling.
4 . The method of claim 1 , further comprising modifying said recombined molecule.
5 . The method of claim 1 , wherein said starting molecules are selected from the group consisting of polypeptides, peptidomimetics, nucleic acids, alkaloids, macrolides, terpenes, macrocycles, fermentation products, and molecules from plant, animal, bacterial, and fungal sources.
6 . The method of claim 1 , wherein at least one of the starting molecules is selected from the group consisting of vancomycin, Rifamycin B, erythromycin, camptothecin, 9-hydroxyellipticine, bisamidophthalanide derivatives, rapamycin, actinomycinD, avermectin B1, phomopsin A, and cytochalasin D.
7 . The method of claim 1 , wherein at least one of said starting molecules is attached to a solid support.
8 . The method of claim 1 , wherein said cleaving is mediated by an enzyme selected from the group consisting of hydrolases, oxidases, reductases, proteases, peptidases, esterases, and mono-oxygenases.
9 . The method of claim 1 , wherein said assembling is mediated by an enzyme selected from the group consisting of lyases, ligases, fumarases, glycosyl transferases, glycosidases, haloperoxidases and halohydrin eposidases.
10 . The method of claim 1 , further comprising screening for a biological activity of said recombined molecule comprising contacting said recombined molecule with a biological target, and determining the effect of said recombined molecule on a property of said biological target.
11 . A library of recombined molecules made according to the method of claim 1 .
12 . A method for screening for a biologically active recombined molecule comprising contacting the library of claim 11 with a biological target and determining the effect of said library on a property of said biological target.
13 . The method of claim 12 , wherein said library is partially purified prior to said contacting.
14 The method of claim 12 further comprising isolating from said library a recombined molecule with said biological activity.
15 . The method of claim 14 further comprising identifying the structure of said recombined molecule with said biological activity.
16 . A biologically active recombined molecule made according to the method of claim 1.Join the waitlist — get patent alerts
Track US2005010029A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.